EBG MedAaustron

What EBG MedAaustron does

EBG MedAustron GmbH (operating as MedAustron) is a cancer treatment and research center headquartered in Wiener Neustadt, Lower Austria, approximately 50 kilometers south of Vienna. It is one of only six facilities worldwide offering both proton and carbon ion beam therapy, and the sole such center in Austria. The company operates a particle accelerator facility originally developed from CERN basic research, adapted for clinical use, and delivers high-precision radiation therapy with millimeter accuracy to cancer patients as an outpatient center. Indication coverage spans pediatric oncology, skull base tumors, central nervous system tumors, head and neck cancers, and since November 2024, uveal/choroidal melanoma via a dedicated proton eye treatment system.

The business combines clinical treatment, non-clinical research, and academic training under one roof. Treatment is delivered directly to patients (Austrian and international, particularly from Central and Eastern Europe where no comparable proton centers exist) through online therapy requests, physician referrals, and a secure patient transfer portal. Non-clinical research services provide beam time access to external scientists under a cooperation agreement with the Austrian Federal Ministry, with 1,056 hours per year allocated in the 2025-2027 research program. MedAustron serves as the teaching and research center for Karl Landsteiner Private University in radiation oncology and medical physics.

The company is indirectly owned by the State of Lower Austria through NÖ Landesgesundheitsagentur, with a supervisory board chaired by Klaus Schneeberger and dual managing directors (Prof. Dr. Eugen B. Hug as Medical Director, and DI Alfred Zens, MBA as commercial/technical Director from March 2025). Treatment costs flow through public health insurance in Austria; research activities are supported by state grants including up to 1.8 million EUR from Lower Austria for 2025-2029. The company has completed over 2,700 treatments since operations began in 2016 and employs 250+ experts from more than 20 nations.

Name

EBG MedAaustron

Legal name

EBG MedAustron GmbH

Website

https://medaustron.at

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

251–500 employees

Short description

EBG MedAustron GmbH is an Austrian state-owned cancer treatment and research center in Wiener Neustadt operating one of only six worldwide facilities offering both proton and carbon ion beam therapy, serving Austrian and Central/Eastern European patients and academic researchers.

Ownership category

akta.pro rank

Product category

Particle Therapy / Radiation Oncology

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Radiation Oncology (HLAKAFAC)

akta.pro secondary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

Keywords

• Particle therapy
• Proton beam therapy
• Carbon ion therapy
• Cancer treatment center
• Radiation oncology

Headquarters

HQ city

Neustadt

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Ion Beam Therapy Treatment: Revenue generated from providing ion therapy (proton and carbon ion) treatments to cancer patients, both Austrian and international. The center operates as an outpatient facility.
2. Clinical Research Services: Research activities supported by external funding, including grants from the State of Lower Austria (up to 1.8 million euros for 2025-2029) and cooperation agreements with federal ministries.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

EBG MedAustron operates a cancer treatment and research center providing high-precision ion beam therapy using protons and carbon ions, the only facility in Austria and one of six worldwide offering both modalities. The center operates a particle accelerator (originally derived from CERN basic research) to deliver targeted radiation therapy that minimizes damage to surrounding healthy tissue, complemented by clinical and non-clinical research programs.

Product overview

MedAustron is a cancer treatment and research center offering ion beam therapy as its core product, the only facility in Austria and one of only six worldwide providing both proton and carbon ion therapy. The center operates a particle accelerator facility in Wiener Neustadt, combining clinical treatment with research capabilities. Key offerings include Proton Beam Therapy and Carbon Ion Therapy for cancer treatment, a specialized Proton Eye Treatment system for uveal melanoma, and Clinical Research Studies generating evidence for ion therapy. Supporting services include Non-Clinical Research Services (providing beam time access to external scientists), a Secure Patient Transfer Portal for health document submission, and an Education and Training Programs for radio-oncologists. The facility has completed over 2,700 treatments since 2016.

Differentiator

Problem solved

Functional benefit

Products and services

• Proton Beam Therapy
• Carbon Ion Therapy
• Proton Eye Treatment (Uveal Melanoma)
• Clinical Research Studies
• Non-Clinical Research Services
• Education and Training Programs

Quantifiable outcome

• Over 2,700 completed treatments since 2016
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• Universitätsklinik für Augenheilkunde und Optometrie (University Clinic for Ophthalmology)minorStrategic or Co-development Partner · 1 November 2025Cooperation for proton therapy for ocular malignancies in Austria, marking the first proton treatment for choroidal melanoma in the country.
• International Particle Therapy AlliancecoreStrategic or Co-development Partner · 1 November 2025MedAustron hosted the 1st International Particle Therapy Alliance Meeting in November 2025, bringing together international particle therapy centers.
• Bundesministerium für Frauen, Wissenschaft und Forschung (Federal Ministry for Women, Science and Research)coreStrategic or Co-development Partner · 1 January 2024Cooperation agreement enabling Austrian research institutions to use MedAustron's particle accelerator infrastructure for research purposes. The agreement regulates access to beam time for research, provided outside clinical operations primarily on weekends.
• Medizinische Universität Wien (MedUni Wien)coreStrategic or Co-development Partner · 1 January 2024Major Austrian medical university collaborating with MedAustron on research projects. External scientists from MedUni Wien work at the MedAustron facility.
• TU Wien (Vienna University of Technology)coreStrategic or Co-development Partner · 1 January 2024Technical university contributing expertise in accelerator physics and related technical fields to MedAustron research programs.
• FH Wiener NeustadtminorStrategic or Co-development Partner · 1 January 2024University of Applied Sciences participating in research collaborations at MedAustron.
• Institut für Hochenergiephysik (Institute for High Energy Physics)minorStrategic or Co-development Partner · 1 January 2024High energy physics institute collaborating on physics-related research at MedAustron.
• Karl Landsteiner Privatuniversität (Karl Landsteiner Private University)coreStrategic or Co-development Partner · 1 January 2024MedAustron serves as the teaching and research center of the Karl Landsteiner Private University of Health Sciences for radiation oncology and medical physics.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Heidelberg Ion-Beam Therapy Center (HIT): HIT operates one of the leading European combined proton and carbon ion therapy facilities in Heidelberg, Germany, treating similar patient indications with comparable particle accelerator technology. It is the closest direct peer to MedAustron in scope, modality mix, and academic hospital affiliation.
• CNAO (Centro Nazionale di Adroterapia Oncologica): CNAO is a national hadrontherapy center in Pavia, Italy, offering both proton and carbon ion therapy with a similar dual clinical-research mission. It is directly comparable to MedAustron as a publicly supported European particle therapy center with a comparable treatment modality mix.
• Paul Scherrer Institute (PSI) Proton Therapy Center: PSI operates one of the longest-running proton therapy facilities in Villigen, Switzerland, treating ocular tumors and other indications with a strong research focus. Its combined clinical-research orientation and narrow specialization make it directly comparable to MedAustron.
• OncoRay (Dresden): OncoRay is a Dresden-based translational research center jointly operated by Helmholtz-Zentrum Dresden-Rossendorf, TU Dresden, and University Hospital Carl Gustav Carus, focused on proton therapy and radiation research. Its research-driven model and university partnership structure closely parallel MedAustron's academic-clinical integration.
• University of Florida Health Proton Therapy Institute: UF Health Proton Therapy Institute in Jacksonville is a major proton-only therapy center affiliated with a major US academic medical system, treating pediatric and adult cancers with a strong clinical research program. It is comparable to MedAustron as an academic-affiliated proton therapy center with high patient throughput.

Broad incumbents

• MD Anderson Proton Therapy Center: MD Anderson Cancer Center operates one of the largest proton therapy facilities globally within a comprehensive cancer hospital. It competes for international referrals and clinical evidence leadership but offers a much broader oncology portfolio beyond radiation therapy.
• Massachusetts General Hospital Burr Proton Therapy Center: Massachusetts General Hospital's Francis H. Burr Proton Therapy Center is a major US proton therapy facility within a large academic medical center. It is comparable as a proton therapy provider with a strong research program, but operates within a broader general hospital portfolio.
• Provision CARES Proton Therapy Centers: Provision Healthcare operates a network of proton therapy centers across the United States with standardized technology deployments. It is comparable as a proton therapy operator but is a commercial, multi-site platform rather than a research-integrated single facility like MedAustron.

Others

• IBA (Ion Beam Applications): IBA is the leading global manufacturer of proton therapy systems and supplies the particle accelerator technology underlying facilities like MedAustron. It is comparable as a critical enabling technology provider rather than a direct treatment service competitor.
• Varian (Siemens Healthineers): Varian, now part of Siemens Healthineers, is a major manufacturer of radiation oncology equipment including proton therapy systems. It is comparable as a key equipment and software provider to particle therapy centers rather than a direct clinical operator.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC_0PJrnG43mn3nKkD5VzFcQ
• Facebookfacebook.com/medaustron
• LinkedInlinkedin.com/company/ebg-medaustron-gmbh
• Instagraminstagram.com/medaustronat

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EBG MedAaustron